Related Experiment Video
Updated: Jun 28, 2026

Fission Yeast as a Platform for Antibacterial Drug Screens Targeting Bacterial Cytoskeleton Proteins
Published on: April 26, 2024
[Evaluation of in vitro antibacterial activity of fosmidomycin and its derivatives]
Abstract:
Unlike the mammals, some species of pathogenic microorganisms synthesize isoprenoids by the mevalonate-independent pathway known as the methyl-erythritol phosphate pathway (MEP). The macromolecules of the polyprenyl compounds play an essential role in the metabolism of the microbial cell. Therefore, the MEP enzymes can be targets for new antibiotics. Antibacterial activity of fosmidomycin, an inhibitor of 1-deoxy-D-xylulose-5-phosphate reductoisomerase (DXR), the key enzyme of MEP in isoprenoid biosynthesis was estimated. By the results of the in vitro experiments the tested microorganisms were divided into susceptible and resistant to fosmidomycin. Vaccinal strains of B. anthracis and practically all the strains of P. aeruginosa were included into the first group. The minimum inhibitory concentrations of fosmidomycin for them determined by the method of serial dilutions were 1-8 mcg/ml. The second group for which the MICs were 16-64 mcg/ml included representatives of Listeria, Yersinia and Burkholderia. The tested species of enteric bacteria, Mycobacterium, Corynebacterium, Campylobacterium and the tularemia vaccinal strain were fosmidomycin resistant. The MICs for them varied from 128 to 512 mcg/ml. Since all the above mentioned bacteria have DXR, resistance to fosmidomycin was conjectured with the difficulty of its delivery to the target in the microbial cell. To increase penetrability of fosmidomycin, various functional groups modifing its hydrophoby were added to the antibiotic molecule. However, no expected increase of the susceptibility to the derivatives was achieved probably because their affinity to DXR lowered. Penetrability of fosmidomycin to the cell was facilitated by using its combinations with compounds influencing the integrity of the bacterial cell membrane. Combined use of fosmidomycin with polymyxin B, chlorhexidine and cetrimide 4-64 times lowered its MICs for the strains of Listeria, Burkholderia and Yersinia.
Insights
Fosmidomycin, an antibiotic targeting the methyl-erythritol phosphate pathway (MEP), shows varied efficacy against bacteria. Combinations with membrane-disrupting agents enhance its activity against resistant strains.
Area of Science:
- Microbiology
- Drug Discovery
- Biochemistry
Background:
- Pathogenic microorganisms utilize the methyl-erythritol phosphate pathway (MEP) for isoprenoid synthesis, distinct from mammals.
- MEP enzymes are potential targets for novel antibiotic development.
- Polyprenyl compounds are crucial macromolecules in microbial cell metabolism.
Purpose of the Study:
- To evaluate the antibacterial activity of fosmidomycin, an inhibitor of 1-deoxy-D-xylulose-5-phosphate reductoisomerase (DXR).
- To investigate the mechanisms of fosmidomycin resistance in various bacterial species.
- To explore strategies for enhancing fosmidomycin's efficacy against resistant pathogens.
Main Methods:
- In vitro susceptibility testing of fosmidomycin against diverse bacterial strains.
- Determination of Minimum Inhibitory Concentrations (MICs) using serial dilution methods.
- Assessment of fosmidomycin derivatives and combination therapies to overcome resistance.
Main Results:
- Bacterial strains exhibited variable susceptibility to fosmidomycin, with MICs ranging from 1 to 512 mcg/ml.
- Vaccinal strains of B. anthracis and P. aeruginosa were susceptible, while Listeria, Yersinia, and Burkholderia showed intermediate resistance.
- Enteric bacteria, Mycobacterium, Corynebacterium, Campylobacterium, and tularemia strains were resistant.
- Modifying fosmidomycin's hydrophoby did not improve efficacy; combination therapy with polymyxin B, chlorhexidine, or cetrimide significantly lowered MICs for resistant strains.
Conclusions:
- Bacterial resistance to fosmidomycin may stem from impaired drug delivery to the DXR target.
- Enhancing fosmidomycin's cellular penetration is key to overcoming resistance.
- Combination therapies with membrane-active agents represent a promising strategy to potentiate fosmidomycin's antibacterial effects.
